Clinical Practice Guidelines for tuberous sclerosis complex‐associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update

Abstract

New clinical issues have been raised through an interval of 7 years from the previous version (2016). In this study, we update the “Clinical Practice Guidelines for tuberous sclerosis complex‐associated renal angiomyolipoma” as a 2023 version under guidance by the Japanese Urological Association. The present guidelines were cooperatively prepared by the Japanese Urological Association and Japanese Society of Tuberous Sclerosis Complex; committee members belonging to one of the two societies or specializing in the treatment of this disease were selected to prepare the guidelines in accordance with the “Guidance for preparing treatment guidelines” published by Minds (2020 version). The “Introduction” consisted of four sections, “Background Questions (BQ)” consisted of four sections, “Clinical Questions (CQ)” consisted of three sections, and “Future Questions (FQ)” consisted of three sections (total: 14 sections). Concerning CQ, an agreement was confirmed through voting by the committee members based on the direction and strength of recommendation, accuracy of evidence, and recommendation comments. The present guidelines were updated based on the current evidence. We hope that the guidelines will provide guiding principles for the treatment of tuberous sclerosis complex‐associated renal angiomyolipoma to many urologists, becoming a foundation for subsequent updating.